Pharmanutra S.p.A.

Equities

PHN

IT0005274094

Pharmaceuticals

Real-time Borsa Italiana 08:50:00 2024-07-08 EDT 5-day change 1st Jan Change
47.95 EUR -2.14% Intraday chart for Pharmanutra S.p.A. 0.00% -14.98%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
PharmaNutra Says Merger of Subsidiaries Becomes Effective MT
PharmaNutra, Junia Pharma and Alesco merger becomes effective AN
Mib slightly up; bond issue for Enel AN
Mib up, Saipem and banks well AN
Pharmanutra expands into Mexico after contract with SMS Pharma AN
PharmaNutra kicks off over EUR1 million buyback plan AN
Milan up tentatively; Leonardo and banks do well AN
Mib pegs 34,300; banking segment well AN
Futures up; focus on inflation data AN
Mib rises and ECB cuts in sight; boost on Zignago AN
Sell on stock markets; Danske revises ECB cut estimates AN
Pharmanutra S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Indices expected to rise ahead of macro data AN
Mib on highs since 2008 dragged by banks AN
PharmaNutra, profit down sharply in quarter; revenues improve AN
Lists in green except Mib; banks good AN
Iveco down on Mib; European stock exchanges in green AN
Futures await bourses up; China holds rates AN
Mib closes bullish; Terna takes top spot AN
PharmaNutra Gets Approvals to Merge Subsidiaries MT
PharmaNutra approves merger of Junia Pharma and Alesco AN
Futures passive; BoJ abandons negative rates. AN
Milan at parity; De Nora on bottom after accounts AN
PharmaNutra increases revenues to double digits in 2023 AN
Pharmanutra S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chart Pharmanutra S.p.A.
More charts
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
49 EUR
Average target price
80.33 EUR
Spread / Average Target
+63.95%
Consensus
  1. Stock Market
  2. Equities
  3. PHN Stock
  4. News Pharmanutra S.p.A.
  5. PharmaNutra Says Merger of Subsidiaries Becomes Effective